Float Short %

17.37

Margin Of Safety %

Put/Call OI Ratio

0.08

EPS Next Q Diff

-0.14

EPS Last/This Y

0.34

EPS This/Next Y

-0.5

Price

9.35

Target Price

22.75

Analyst Recom

1.2

Performance Q

-28.17

Relative Volume

0.42

Beta

0.95

Ticker: STOK

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	STOK	11.28	0.31	0.00	5526
2024-12-20	STOK	11.68	0.30	332.50	5656
2024-12-23	STOK	11.61	0.06	0.00	4419
2024-12-24	STOK	11.32	0.06	0.00	4424
2024-12-26	STOK	11.22	0.06	0.00	4569
2024-12-27	STOK	11.05	0.06	0.00	4678
2024-12-30	STOK	10.83	0.06	0.00	4678
2024-12-31	STOK	11.06	0.06	2.00	4702
2025-01-02	STOK	11.27	0.06	0.00	4708
2025-01-03	STOK	11.49	0.04	0.00	6647
2025-01-06	STOK	11.02	0.04	0.00	6816
2025-01-07	STOK	9.3	0.04	0.34	6822
2025-01-08	STOK	8.96	0.06	0.08	7280
2025-01-09	STOK	8.96	0.06	0.08	7280
2025-01-10	STOK	9	0.07	0.02	6755
2025-01-13	STOK	8.91	0.07	1.46	7390
2025-01-14	STOK	8.67	0.07	1.63	7448
2025-01-15	STOK	9.48	0.07	0.31	7484
2025-01-16	STOK	9.43	0.07	0.28	7495
2025-01-17	STOK	9.35	0.08	262.00	7882
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	STOK	11.28	7.3	-	-2.05
2024-12-20	STOK	11.71	7.3	-	-2.05
2024-12-23	STOK	11.61	8.5	-	-2.04
2024-12-24	STOK	11.32	8.5	-	-2.04
2024-12-26	STOK	11.24	8.5	-	-2.04
2024-12-27	STOK	11.06	8.5	-	-2.04
2024-12-30	STOK	10.81	8.5	-	-2.04
2024-12-31	STOK	11.06	8.5	-	-2.04
2025-01-02	STOK	11.30	8.5	-	-2.04
2025-01-03	STOK	11.49	8.5	-	-2.04
2025-01-06	STOK	11.02	8.5	-	-2.04
2025-01-07	STOK	9.31	8.5	-	-2.04
2025-01-08	STOK	8.96	8.5	-	-2.04
2025-01-09	STOK	8.96	8.5	-	-2.04
2025-01-10	STOK	9.01	8.5	-	-2.04
2025-01-13	STOK	8.91	8.5	-	-2.04
2025-01-14	STOK	8.68	8.5	-	-2.04
2025-01-15	STOK	9.49	8.5	-	-2.04
2025-01-16	STOK	9.44	8.5	-	-2.04
2025-01-17	STOK	9.35	8.5	-	-2.04
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	STOK	-14.75	-7.30	16.39
2024-12-20	STOK	-14.75	-7.30	16.39
2024-12-23	STOK	-14.34	-7.31	16.39
2024-12-24	STOK	-14.34	-7.31	16.39
2024-12-26	STOK	-15.07	-7.31	17.65
2024-12-27	STOK	-14.75	-7.31	17.65
2024-12-30	STOK	-25.77	-7.20	17.65
2024-12-31	STOK	-25.77	-7.20	17.65
2025-01-02	STOK	-25.46	-7.20	17.65
2025-01-03	STOK	-25.46	-7.20	17.65
2025-01-06	STOK	-25.04	-7.46	16.84
2025-01-07	STOK	-28.66	-7.46	16.84
2025-01-08	STOK	-28.98	-7.46	16.85
2025-01-09	STOK	-28.98	-7.46	16.85
2025-01-10	STOK	-28.98	-7.46	16.85
2025-01-13	STOK	-28.98	-7.46	17.37
2025-01-14	STOK	-28.98	-7.46	17.37
2025-01-15	STOK	-28.98	-7.46	17.37
2025-01-16	STOK	-28.98	-7.46	17.37
2025-01-17	STOK	-28.98	-7.46	17.37
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.47

Avg. EPS Est. Current Quarter

-0.55

Avg. EPS Est. Next Quarter

-0.6

Insider Transactions

-28.98

Institutional Transactions

-7.46

Beta

0.95

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

86.9

Max Drawdown 5-Year %

-95.2

Target Price

22.75

P/E

Forward P/E

PEG

P/S

29.62

P/B

2.13

P/Free Cash Flow

EPS

-2.1

Average EPS Est. Cur. Y

-2.04

EPS Next Y. (Est.)

-2.54

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-629.86

Relative Volume

0.42

Return on Equity vs Sector %

-64.5

Return on Equity vs Industry %

-51.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

Stoke Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 110

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

stock quote shares STOK – Stoke Therapeutics, Inc. Stock Price stock today

news today STOK – Stoke Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch STOK – Stoke Therapeutics, Inc. yahoo finance google finance

stock history STOK – Stoke Therapeutics, Inc. invest stock market

stock prices STOK premarket after hours

ticker STOK fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: STOK

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y